Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;37(1):189-196.
doi: 10.1007/s10555-017-9719-4.

Current perspectives on bone metastases in castrate-resistant prostate cancer

Christopher Logothetis  1 , Michael J Morris  2 , Robert Den  3 , Robert E Coleman  4
Affiliations
Review

Current perspectives on bone metastases in castrate-resistant prostate cancer

Christopher Logothetis et al. Cancer Metastasis Rev. 2018 Mar.

Abstract

Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intensive therapy. This unmet need has led to recent advances in therapy aimed at treating bone metastases resulting from prostate cancer. The bone microenvironment lends itself to metastases in castrate-resistant prostate cancer, as a result of complex interactions between the microenvironment and tumor cells. The development of 223radium dichloride (Ra-223) to treat symptomatic bone metastases has improved survival in men with metastatic castrate-resistant prostate cancer. Moreover, Ra-223 may have effects on the tumor microenvironment that enhance its activity. Ra-223 treatment has been shown to prolong survival, and its effects on the immune system are under investigation. Because prostate cancer affects a sizable portion of the adult male population, understanding how it metastasizes to bone is an important step in advancing therapy. Clinical trials that are underway should yield new information on whether Ra-223 synergizes effectively with immunotherapy agents and whether Ra-223 has enhancing effects on the immune system in patients with prostate cancer.

Keywords: Bone metastases; Castrate-resistant prostate cancer; Radium-223; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Christopher Logothetis has received commercial grants from Astellas, Janssen, Bayer, Bristol Myers Squibb, Medivation, and Sanofi. Michael J. Morris is a paid consultant for Advanced Accelerator Applications and an unpaid consultant for Astellas, Endocyte, Progenics, and Tokai. Dr. Morris’ institution has received support from Bayer, Endocyte, and Progenics. Robert Den has received support from GenomeDx and Medivation and has served on the advisory board for Bayer, as well as the Bayer Speaker’s Bureau. Robert E. Coleman’s institution has received research funding from Bayer.

Figures

Fig. 1
Fig. 1
Matrix metalloproteinases (MMPs), chemokine receptor (CXCR)-4, vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF) target metastatic tumor cells to bone and facilitate their survival within the bone microenvironment. Physical factors within bone, including hypoxia, acidic pH, and extracellular Ca2+, and bone-derived growth factors, such as tumor growth factor (TGF)-β and insulin-like growth factors (IGFs), activate tumor expression of osteoblast-stimulatory factors, such as VEGF, platelet-derived growth factor (PDGF), and endothelin-1 (ET-1). Osteoclast-stimulatory factors can also be increased, which in turn release factors that promote tumor growth in bone. Republished with permission of the American Association of Cancer Research, from [10]. Permission conveyed through Copyright Clearance Center, Inc.
Fig. 2
Fig. 2
Kaplan–Meier estimates of overall survival (OS) show that treatment with Ra-223 increased the median OS significantly relative to placebo, from 11.3 to 14.9 months (P < .001; hazard ratio, 0.70; 95% confidence interval, 0.58–0.83). Republished with permission of [15]. Permission conveyed through Copyright Clearance Center, Inc.
See this image and copyright information in PMC

References

    1. National Cancer Institute. (2017). SEER Cancer Stat Facts: prostate cancer. http://seer.cancer.gov/statfacts/html/prost.html. Accessed August 9, 2017.
    1. Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747. - DOI - PMC - PubMed
    1. Aparicio AM, Shen L, Tapia ELN, Lu J-F, Chen H-C, Zhang J, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clinical Cancer Research. 2016;22(6):1520–1530. doi: 10.1158/1078-0432.CCR-15-1259. - DOI - PMC - PubMed
    1. Tzelepi V, Zhang J, Lu J-F, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clinical Cancer Research. 2012;18(3):666–677. doi: 10.1158/1078-0432.CCR-11-1867. - DOI - PMC - PubMed
    1. Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (New York, N.Y.) 2017;355(6320):84–88. doi: 10.1126/science.aah4307. - DOI - PMC - PubMed